|
|
|
|
|
09.06.26 - 14:36
|
Vergent Bioscience Names Adam Gridley as Chief Executive Officer (Business Wire)
|
|
|
Phase 3 clinical trial progress and strengthened leadership team position Vergent for its next phase of growth toward commercialization and pipeline developmentMINNEAPOLIS--(BUSINESS WIRE)--Vergent Bioscience, a clinical-stage biotechnology company advancing molecularly targeted intraoperative imaging, today announced the appointment of Adam Gridley as President and Chief Executive Officer. Mr. Gridley succeeds John Santini, Ph.D., who will transition to the role of Chief Technology Officer, continuing to lead the company's scientific innovation and long-term technology strategy.
Mr. Gridley brings more than 30 years of commercial and late-stage clinical experience in the biotechnology, medical device and pharmaceutical industries, leading venture capital-backed startups to fully integrated public commercial organizations. He previously held CEO roles at Allay Therapeutics, a drug delivery biotechnology company; Entera Bio, an oral biologics company; and Histogenics, a cell therapy and biologics company....
|
|
|
28.05.26 - 14:54
|
Entera′s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation (GlobeNewswire EN)
|
|
|
TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide pipeline have been accepted for presentation at ENDO 2026, the annual meeting of the Endocrine Society, taking place June 13-16, 2026 in Chicago, Illinois, USA. Notably, new clinical data supporting Entera's single EB613 tablet as the final candidate for its planned Phase 3 study in postmenopausal women with osteoporosis was selected for a Late Breaking Oral Presentation....
|
|
|
|
|
|
|
14.04.26 - 14:48
|
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 (GlobeNewswire EN)
|
|
|
TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 (oral PTH (1-34) tablet), on Monday, April 20, 2026 at 11:00 AM Eastern Time....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
